Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

A new study published in Pharmaceutics ( shows that LEON’s FR-JET® modular mixer addresses key manufacturing challenges by ...

A new study shows human immune systems differ across populations, raising new questions for medicine and global drug research ...

Glioblastoma (GBM) is the most common and highly aggressive primary brain tumor in adults. MicroRNAs (miRNAs) are pleiotropic post-transcriptional regulators of oncogenic pathways, and frequently lose ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF ...

Researchers at WashU Medicine and their collaborators have created an immune cell atlas of multiple myeloma, a cancer of the ...

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma ...